CDER MAPP describes roles and responsibilities in reviewing quality portions of BLAs
This article was originally published in The Gold Sheet
FDA's Center for Drug Evaluation and Research has issued a policy guide that outlines the roles of different organizations in reviewing the quality sections of new biologics license applications and supplements. It addresses the responsibilities of the Office of Biotechnology Products (OBP) in the Office of Pharmaceutical Science (OPS) and the Division of Manufacturing Product Quality (DMPQ) in the Office of Compliance in reviewing these applications. The MAPP is meant to "provide a team approach to product quality evaluation of biologics licensing application, and defines clear roles and responsibilities." For example, the DMPQ assessment lead is responsible for microbial method qualification and the OBP assessment lead is responsible for overall process design and flow for the drug substance and the non-sterility parameters of the drug product. The MAPP took effect on Dec. 22 and the policy will be re-evaluated after one year
You may also be interested in...
Janet Woodcock, director of FDA's Center for Drug Evaluation and Research, says her top priority this year is to launch an overall quality system for the center. "This will result in appreciable improvements in consistency of our regulatory approach over time," she told the WCBP Symposium on Jan. 25 in Washington
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.